Clinical trial
Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients…
NCT00274742 · Amgen Research (Munich) GmbH, Industry · Completed
Key facts
| NCT number | NCT00274742 |
|---|---|
| Title | Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL |
| Official title | An Open-label, Multi-center Phase I Study to Investigate the Tolerability and Safety of a Continuous Infusion of the Bispecific T-cell Engager MT103 in Patients With Relapsed Non-Hodgkin's Lymphoma (NHL) |
| Lead sponsor | Amgen Research (Munich) GmbH, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma, Relapsed |
| Intervention type | Biological |
| Interventions | Blinatumomab (MT103) |
| Enrollment | 76 |
| Start date | Jun 1, 2004 |
| Primary completion | Aug 1, 2011 |
| Completion | Apr 1, 2012 |
| First posted | Jan 11, 2006 |
| Last update posted | Jan 16, 2015 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: